Groupe Francophone des Myelodysplasies

Quick facts

Phase 2 pipeline

• Azacitidine combined to Lenalidomide · Oncology
  Azacitidine and lenalidomide work together to restore normal gene expression in myelodysplastic syndrome cells through DNA methylation inhibition and immunomodulation.
• BST-236
• Luspatercept Injection [Reblozyl] · Oncology
  Luspatercept is a recombinant fusion protein that acts as a ligand trap for members of the TGF-β superfamily, modulating Smad2/3 signaling to enhance erythroid maturation.
• Momelotinib treatment
• SGI-110 administration

Phase 1 pipeline

• azacitidine and idarubicin
• Azacitidine and LDE255
• CPX-351 in cohort A
• CPX-351 in cohort B
• Deferasirox, Vitamin D and Azacitidine

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Groupe Francophone des Myelodysplasies portfolio CI brief
• Groupe Francophone des Myelodysplasies pipeline updates RSS

Related

• Sector hub: All tracked pharma companies